Pyruvate Dehydrogenase Inhibition Leads to Decreased Glycolysis, Increased Reliance on Gluconeogenesis and Alternative Sources of Acetyl-CoA in Acute Myeloid Leukemia.
Pyruvate Dehydrogenase Inhibition Leads to Decreased Glycolysis, Increased Reliance on Gluconeogenesis and Alternative Sources of Acetyl-CoA in Acute Myeloid Leukemia.
复制标题
作者：
Acute myeloid leukemia (AML) is an aggressive cancer with poor outcomes that needs new treatments. One new approach to treat AML is to target its metabolism. A large phase III clinical trial using a metabolic inhibitor, devimistat, did not show any benefit for patients. One reason could be that AML cells can change their metabolism in the presence of devimistat. This study looked at how AML cells change their metabolism when devimistat is present. It is hoped that, by understanding how AML cells resist devimistat, new approaches can be developed. Acute myeloid leukemia (AML) is an aggressive disease characterized by poor outcomes and therapy resistance. Devimistat is a novel agent that inhibits pyruvate dehydrogenase complex (PDH). A phase III clinical trial in AML patients combining devimistat and chemotherapy was terminated for futility, suggesting AML cells were able to circumvent the metabolic inhibition of devimistat. The means by which AML cells resist PDH inhibition is unknown. AML cell lines treated with devimistat or deleted for the essential PDH subunit, PDHA, showed a decrease in glycolysis and decreased glucose uptake due to a reduction of the glucose transporter GLUT1 and hexokinase II. Both devimistat-treated and PDHA knockout cells displayed increased sensitivity to 2-deoxyglucose, demonstrating reliance on residual glycolysis. The rate limiting gluconeogenic enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) was significantly upregulated in devimistat-treated cells, and its inhibition increased sensitivity to devimistat. The gluconeogenic amino acids glutamine and asparagine protected AML cells from devimistat. Non-glycolytic sources of acetyl-CoA were also important with fatty acid oxidation, ATP citrate lyase (ACLY) and acyl-CoA synthetase short chain family member 2 (ACSS2) contributing to resistance. Finally, devimistat reduced fatty acid synthase (FASN) activity. Taken together, this suggests that AML cells compensate for PDH and glycolysis inhibition by gluconeogenesis for maintenance of essential glycolytic intermediates and fatty acid oxidation, ACLY and ACSS2 for non-glycolytic production of acetyl-CoA. Strategies to target these escape pathways should be explored in AML.
登录
查看更多内容
抑制线粒体翻译是人类急性髓样白血病的治疗策略。
影响因子：
50.3
作者：
Skrtić M;Sriskanthadevan S;Jhas B;Gebbia M;Wang X;Wang Z;Hurren R;Jitkova Y;Gronda M;Maclean N;Lai CK;Eberhard Y;Bartoszko J;Spagnuolo P;Rutledge AC;Datti A;Ketela T;Moffat J;Robinson BH;Cameron JH;Wrana J;Eaves CJ;Minden MD;Wang JC;Dick JE;Humphries K;Nislow C;Giaever G;Schimmer AD
通讯作者：
Schimmer AD
影响因子：
5.7
作者：
Zavorka Thomas ME;Lu X;Talebi Z;Jeon JY;Buelow DR;Gibson AA;Uddin ME;Brinton LT;Nguyen J;Collins M;Lodi A;Sweeney SR;Campbell MJ;Sweet DH;Sparreboom A;Lapalombella R;Tiziani S;Baker SD
通讯作者：
Baker SD
影响因子：
16.6
作者：
Anderson R;Miller LD;Isom S;Chou JW;Pladna KM;Schramm NJ;Ellis LR;Howard DS;Bhave RR;Manuel M;Dralle S;Lyerly S;Powell BL;Pardee TS
通讯作者：
Pardee TS
DOI：
10.1073/pnas.1003428107
发表时间：
2010-05-11
影响因子：
11.1
作者：
Weinberg, Frank;Hamanaka, Robert;Chandel, Navdeep S.
通讯作者：
Chandel, Navdeep S.
影响因子：
16
作者：
Vincent, Emma E.;Sergushichev, Alexey;Jones, Russell G.
通讯作者：
Jones, Russell G.